These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21950360)

  • 21. Post-finasteride syndrome.
    Gray SL; Semla TP
    BMJ; 2019 Aug; 366():l5047. PubMed ID: 31399423
    [No Abstract]   [Full Text] [Related]  

  • 22. A serious side effect of a potentially widely used cosmetic product.
    Smith VM; Cockshoot D
    Clin Exp Dermatol; 2015 Apr; 40(3):347-8. PubMed ID: 25622515
    [No Abstract]   [Full Text] [Related]  

  • 23. Decreased alcohol consumption among former male users of finasteride with persistent sexual side effects: a preliminary report.
    Irwig MS
    Alcohol Clin Exp Res; 2013 Nov; 37(11):1823-6. PubMed ID: 23763349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
    Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R
    N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880
    [No Abstract]   [Full Text] [Related]  

  • 25. Finasteride use and acute pancreatitis in Taiwan.
    Lai SW; Lai HC; Lin CL; Liao KF
    J Clin Pharmacol; 2015 Jun; 55(6):657-60. PubMed ID: 25573785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing finasteride-associated sexual dysfunction using the FAERS database.
    Gupta AK; Carviel J; MacLeod MA; Shear N
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1069-1075. PubMed ID: 28300347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further Studies of Effects of Finasteride on Mood and Suicidal Risk.
    Baldessarini RJ; Pompili M
    J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):687-688. PubMed ID: 34735101
    [No Abstract]   [Full Text] [Related]  

  • 28. 'Post-finasteride syndrome': what to tell our female patients?
    Mervis JS; Borda LJ; Miteva M
    Br J Dermatol; 2018 Sep; 179(3):785-786. PubMed ID: 29624646
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate, baldness drugs linked to sexual dysfunction.
    Kuehn BM
    JAMA; 2012 May; 307(18):1903. PubMed ID: 22570451
    [No Abstract]   [Full Text] [Related]  

  • 30. Is semen analysis necessary prior to initiation of finasteride treatment?
    Lobo OC; Mysore V
    Indian J Dermatol Venereol Leprol; 2019; 85(3):310-311. PubMed ID: 30971531
    [No Abstract]   [Full Text] [Related]  

  • 31. Non-tumoural parenchyma in Leydig cell tumours: pathogenetic considerations.
    Cajaiba MM; Reyes-Múgica M; Rios JC; Nistal M
    Int J Androl; 2008 Jun; 31(3):331-6. PubMed ID: 17573846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant interstitial (Leydig) cell tumour of the testis--a case report.
    Deodhar KK; Naresh KN
    Indian J Pathol Microbiol; 1997 Jan; 40(1):67-9. PubMed ID: 9145617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of finasteride with prostate cancer: A systematic review and meta-analysis.
    Wang L; Lei Y; Gao Y; Cui D; Tang Q; Li R; Wang D; Chen Y; Zhang B; Wang H
    Medicine (Baltimore); 2020 Apr; 99(15):e19486. PubMed ID: 32282699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up.
    Rossi A; Cantisani C; Scarnò M; Trucchia A; Fortuna MC; Calvieri S
    Dermatol Ther; 2011; 24(4):455-61. PubMed ID: 21910805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The novel hormone INSL3 is expressed in human testicular Leydig cell tumors: a clinical and immunohistochemical study.
    Rossato M; Tavolini IM; Calcagno A; Gardiman M; Dal Moro F; Artibani W
    Urol Oncol; 2011; 29(1):33-7. PubMed ID: 19110449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of finasteride users in comparison with nonusers: A Nordic nationwide study based on individual-level data from Denmark, Finland, and Sweden.
    Kjaerulff TM; Ersbøll AK; Pukkala E; Bolin K; Green A; Emneus M; Brasso K; Iversen P; Thygesen LC
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):453-460. PubMed ID: 32048414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contraindicated use of 5-alpha-reductase inhibitors in women.
    Teichert M; van Puijenbroek E; Stricker BH
    Br J Clin Pharmacol; 2017 Feb; 83(2):429-431. PubMed ID: 27567019
    [No Abstract]   [Full Text] [Related]  

  • 39. Leydig cell tumor: a report of two cases with unusual presentation.
    Sengupta S; Chatterjee U; Sarkar K; Chatterjee S; Kundu A
    Indian J Pathol Microbiol; 2010; 53(4):796-8. PubMed ID: 21045421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Hair Loss With Suicidality and Psychological Adverse Events vs Finasteride Use.
    Choi JW; Huh CH; Choi GS
    JAMA Dermatol; 2021 Jun; 157(6):737-738. PubMed ID: 33950168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.